AKT is a therapeutic target in myeloproliferative neoplasms
暂无分享,去创建一个
Qiang Wen | Ayalew Tefferi | Ross L. Levine | R. Levine | A. Tefferi | Q. Wen | J. Altman | Zan Huang | T. Lasho | A. Pardanani | P. Koppikar | J. Crispino | I. Khan | Benjamin H Goldenson | M. Stankiewicz | Sandeep Gurbuxani | Benjamin Goldenson | Rachael Schultz | Laure Gilles | Priya Koppikar | Animesh Pardanani | Brady Stein | S. Gurbuxani | Zan Huang | Lauren Diebold | John D. Crispino | L. Gilles | Rachael F Schultz | Lauren P. Diebold | C. Finke | B. Stein | Irum Khan | Monika J. Stankiewicz | Christy M. Finke | Terra L. Lasho | Jessica K. Altman | Priya Koppikar
[1] G. Daley,et al. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.
[2] B. Druker,et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. , 2010, Blood.
[3] R. Levine,et al. Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.
[4] V. Najfeld,et al. Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis , 2011 .
[5] J. Renauld,et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors , 2011, Haematologica.
[6] Jeffrey A. Engelman,et al. Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.
[7] K. Bhalla,et al. Phase II trial of panobinostat, an oral pan‐deacetylase inhibitor in patients with primary myelofibrosis, post–essential thrombocythaemia, and post–polycythaemia vera myelofibrosis , 2013, British journal of haematology.
[8] Tannishtha Reya,et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.
[9] R. Mesa,et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. , 2005, Blood.
[10] Andrew Kasarskis,et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.
[11] Ben S. Wittner,et al. A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.
[12] D. Frank,et al. Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells , 2012, Leukemia.
[13] W. Vainchenker,et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. , 1997, Blood.
[14] H. Pircher,et al. Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.
[15] Paul Workman,et al. Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.
[16] A. Cumano,et al. Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.
[17] B. Ebert,et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. , 2011, Blood.
[18] Jordi Rodon,et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Christian Steidl,et al. Cooperative epigenetic modulation by cancer amplicon genes. , 2010, Cancer cell.
[20] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[21] J. Griffin,et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms , 2011, Leukemia.
[22] J. Bromberg,et al. Targeting the interleukin-6/Jak/stat pathway in human malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] K. Uozumi,et al. Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles , 2000, Leukemia.
[24] M. García-Delgado,et al. CBL mutations in myeloproliferative neoplasms are also found in the gene’s proline-rich domain and in patients with the V617FJAK2 , 2012, Haematologica.
[25] A. Green,et al. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. , 2011, Blood.
[26] D. Gilliland,et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L , 2012, Leukemia.
[27] K. Bhalla,et al. Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F , 2010 .
[28] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[29] J. McCubrey,et al. Cancer esearch apeutics , Targets , and Chemical Biology ivity of the Novel Dual Phosphatidylinositol 3-Kinase / malian Target of Rapamycin Inhibitor NVP-BEZ 235 R inst T-Cell Acute Lymphoblastic Leukemia , 2010 .
[30] V. Martinelli,et al. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia. , 2010, Blood.
[31] T. Barbui,et al. A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms , 2010, British journal of haematology.
[32] R. Levine,et al. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.
[33] Jen-Chin Wang,et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis , 2008, Leukemia & lymphoma.
[34] D. Yan,et al. Critical requirement for Stat5 in a mouse model of polycythemia vera. , 2012, Blood.
[35] R Berger,et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.
[36] O. Abdel-Wahab,et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. , 2010, Blood.
[37] W. Vainchenker,et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. , 2004, Experimental hematology.
[38] Jonathan Chernoff,et al. Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2011 .
[39] T. Barbui,et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy , 2013, British journal of haematology.
[40] Qingshan Li,et al. Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.
[41] Angela G. Fleischman,et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. , 2011, Blood.
[42] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[43] Michael G. Kharas,et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.
[44] M. Cazzola,et al. Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera , 2012 .
[45] D. Gilliland,et al. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients , 2008, Leukemia.
[46] K. Shokat,et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. , 2008, The Journal of clinical investigation.
[47] M. Boissinot,et al. Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F , 2011, Oncogene.
[48] R. Schreiber,et al. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.
[49] W. Vainchenker,et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. , 2008, Blood.
[50] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[51] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[52] A. Zelenetz,et al. Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[53] J. Liao,et al. MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis , 2011, Molecular Cancer Therapeutics.
[54] Xiaomei Ma,et al. Prevalence of polycythemia vera and essential thrombocythemia , 2007, American journal of hematology.
[55] Bianca Sperl,et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.
[56] W. Vainchenker,et al. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. , 2006, Blood.
[57] M. Warmuth,et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. , 2008, Cancer cell.
[58] T. Barbui,et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). , 2008, Leukemia.
[59] Z. Estrov,et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2010, Blood.
[60] W. Vainchenker,et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.
[61] H. Kantarjian,et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. , 2010, Blood.
[62] D. Barber,et al. Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor , 2012, PloS one.
[63] N. Rosen,et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[64] M. Loh,et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[65] D. Gilliland,et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.
[66] Michael Peyton,et al. Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.
[67] J. Rossjohn,et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. , 2006, Blood.
[68] J. McCubrey,et al. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia , 2012, Leukemia.
[69] P. D. Dal Cin,et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[70] S. Fiering,et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. , 2009, Blood.
[71] M. Cazzola,et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.
[72] W. Vainchenker,et al. New mutations and pathogenesis of myeloproliferative neoplasms. , 2011, Blood.
[73] P. Marynen,et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. , 2000, Cancer research.
[74] R. V. van Etten,et al. Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F , 2006, PloS one.
[75] P. Campbell,et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. , 2008, Blood.
[76] J.,et al. The New England Journal of Medicine , 2012 .
[77] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[78] A. Tefferi,et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.
[79] L. Happerfield,et al. Phospho‐STAT5 and phospho‐Akt expression in chronic myeloproliferative neoplasms , 2009, British journal of haematology.
[80] P. Guglielmelli,et al. mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms , 2013, PloS one.
[81] Erin F. Simonds,et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.
[82] E. Clappier,et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.
[83] Y. E. Chin,et al. Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue , 2005, Science.
[84] Sandra A. Moore,et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. , 2008, Cancer cell.
[85] T. Barbui,et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. , 2011, Blood.
[86] J. Downing,et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.
[87] A. Tefferi,et al. Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis , 2012, American journal of hematology/oncology.
[88] J. Tamburini,et al. Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.
[89] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[90] J. Laubach,et al. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. , 2009, Experimental hematology.
[91] C. Creighton,et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. , 2011, Cancer research.
[92] Catriona Jamieson,et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells , 2013, Molecular Cancer Therapeutics.
[94] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[95] B. Katzenellenbogen,et al. Direct Acetylation of the Estrogen Receptor α Hinge Region by p300 Regulates Transactivation and Hormone Sensitivity* , 2001, The Journal of Biological Chemistry.
[96] N. Mahmud,et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. , 2007, Blood.
[97] J. Marine,et al. Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.
[98] R. DePinho,et al. Crosstalk between NOTCH and AKT signaling during murine megakaryocyte lineage specification. , 2011, Blood.
[99] Chae Un Kim,et al. Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases , 2013, Nature Structural &Molecular Biology.
[100] A. Tefferi. Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up? , 2011, Leukemia.
[101] David Olmos,et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] I. Weissman,et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[103] V. Najfeld,et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post‐polycythaemia vera/essential thrombocythaemia myelofibrosis (post‐PV/ET MF) , 2013, British journal of haematology.
[104] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[105] A. Tefferi. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. , 2012, Blood.
[106] P. Doherty,et al. Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.
[107] B. Bernstein,et al. Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy , 2011, Nature.
[108] W. Leonard,et al. Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.
[109] P. Atadja,et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. , 2009, Blood.
[110] P. Guglielmelli,et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients , 2011, Leukemia.
[111] Eric Vangrevelinghe,et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition , 2011, The Journal of experimental medicine.
[112] Sandra A. Moore,et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.
[113] Simion I. Chiosea,et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. , 2012, Cancer discovery.
[114] D. Birnbaum,et al. Mutations of ASXL1 gene in myeloproliferative neoplasms , 2009, Leukemia.
[115] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[116] P. Campbell,et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. , 2010, Blood.
[117] S. Armstrong,et al. Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. , 2012, Cell stem cell.
[118] K. Bhalla,et al. Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells , 2011, Clinical Cancer Research.
[119] A. Deblasio,et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. , 2011, Cancer cell.
[120] P. Majumder,et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.
[121] A. Lowell,et al. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. , 2005, Cancer research.
[122] Ernesta Dammassa,et al. JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease , 2013, Clinical Cancer Research.
[123] M. Cazzola,et al. Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.
[124] Hongwei Wang,et al. Epidemiology of myeloproliferative neoplasms in the United States , 2014, Leukemia & lymphoma.
[125] M. Loh,et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. , 2005, Blood.
[126] Torsten Haferlach,et al. Activating CBL mutations are associated with a distinct MDS/MPN phenotype , 2012, Annals of Hematology.
[127] R. Mesa,et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis , 2011, Leukemia.
[128] M. Baccarani,et al. Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies , 2011 .
[129] D. Gary Gilliland,et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders , 2007, Nature Reviews Cancer.
[130] M. Jensen,et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms , 2010, Leukemia & lymphoma.
[131] R. Kralovics,et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. , 2006, Blood.
[132] K. Anderson,et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. , 2009, Blood.
[133] J. Fay,et al. American Society for Blood and Marrow Transplantation guidelines for training. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[134] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[135] J. Crispino,et al. AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL , 2013, Leukemia.
[136] K. Ross,et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. , 2010, The Journal of clinical investigation.